Top of the morning to you, and a fine one it is. Once again, clear blue skies and comfortable breezes are enveloping the Pharmalot campus on what is a relatively balmy start to the day. Hard to believe, but it appears that “sprinter” has finally arrived. What is sprinter? You know, that pivotal moment when winter blurs into spring. We hope we are not calling this prematurely, but we feel this deserves another cup of stimulation. Our choice today is coconut. Meanwhile, here are some tidbits. Hope your day goes well, and stay safe — wear a mask. …

Moderna (MRNA) is moving ahead with a modified version of its Covid-19 vaccine meant to protect against an emerging strain of the virus and plans to start a clinical trial as soon as regulators give a green light, STAT writes. Lab tests suggested the Moderna vaccine confers less protection against a variant known as B.1.351 than other strains. Pfizer (PFE) reported similar findings with its shot, and human trials conducted by Johnson & Johnson (JNJ) and Novavax (NVAX) also suggest vaccines designed for the original strain are less effective against B.1.351.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]